PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.95%
R&D change of 26.95% while RVPH maintains spending. Bruce Berkowitz would investigate effectiveness.
24.63%
G&A change of 24.63% while RVPH maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
3.65%
Other expenses change of 3.65% while RVPH maintains costs. Bruce Berkowitz would investigate efficiency.
26.14%
Operating expenses growth while RVPH reduces costs. John Neff would investigate differences.
26.14%
Total costs growth while RVPH reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
3.65%
D&A change of 3.65% while RVPH maintains D&A. Bruce Berkowitz would investigate efficiency.
-26.20%
EBITDA decline while RVPH shows 82.55% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Operating income decline while RVPH shows 82.55% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-1.70%
Other expenses reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine advantage.
-26.43%
Pre-tax income decline while RVPH shows 232.58% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.43%
Net income decline while RVPH shows 232.58% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-26.52%
EPS decline while RVPH shows 224.74% growth. Joel Greenblatt would examine position.
-26.52%
Diluted EPS decline while RVPH shows 224.74% growth. Joel Greenblatt would examine position.
0.09%
Share count reduction exceeding 1.5x RVPH's 6.23%. David Dodd would verify capital allocation.
0.09%
Diluted share reduction exceeding 1.5x RVPH's 6.23%. David Dodd would verify capital allocation.